Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts

Chunlong Zhang†, Yuxi Zhang†, Guiyuan Tan†, Wanqi Mi, Xiaoling Zhong, Yu Zhang, Ziyang Zhao, Feng Li*, Yanjun Xu* and Yunpeng Zhang*

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China

Glioma is the most common malignant tumor of the central nervous system. Tumor purity is a source of important prognostic factor for glioma patients, showing the key roles of the microenvironment in glioma prognosis. In this study, we systematically screened functional characterization related to the tumor immune microenvironment and constructed a risk model named Glioma MicroEnvironment Functional Signature (GMEFS) based on eight cohorts. The prognostic value of the GMEFS model was also verified in another two glioma cohorts, glioblastoma (GBM) and low-grade glioma (LGG) cohorts, from The Cancer Genome Atlas (TCGA). Nomograms were established in the training and testing cohorts to validate the clinical use of this model. Furthermore, the relationships between the risk score, intrinsic molecular subtypes, tumor purity, and tumor-infiltrating immune cell abundance were also evaluated. Meanwhile, the performance of the GMEFS model in glioma formation and glioma recurrence was systematically analyzed based on 16 glioma cohorts from the Gene Expression Omnibus (GEO) database. Based on multiple-cohort integrated analysis, risk subpathway signatures were identified, and a drug–subpathway association network was further constructed to explore candidate therapy target regions. Three subpathways derived from Focal adhesion (path: 04510) were identified and contained known targets including platelet derived growth factor receptor alpha (PDGFRA), epidermal growth factor receptor (EGFR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). In conclusion, the novel functional signatures identified in this study could serve as a robust prognostic biomarker, and this study provided a framework to identify candidate therapeutic target regions, which further guide glioma patients’ clinical decision.

Keywords: glioma, immune microenvironment, prognosis, subpathway, multiple cohorts

INTRODUCTION

Glioma is the most common malignant tumor of the central nervous system (CNS), accounting for 30% (80%) of all brain (malignant) tumors, which displayed the representative characteristics of strong genetic heterogeneity, high mortality, and chemotherapy resistance (1, 2). According to the World Health Organization (WHO) criteria, glioma tumors are histologically separated into Grade I
through IV. Despite significant improvements in the glioma clinical treatment strategy, the median survival remains poor, particularly for those with glioblastoma (GBM, the grade IV of glioma). Patients with GBM exhibit a median survival of approximately 1 year and display poor responses to nearly all clinical therapies (3). Therefore, it is necessary to dissect the inner biological mechanism involved in glioma patients’ survival and identify a novel and robust predictive signature for clinical treatment guidance.

Glioma tissue included both cancer cells and non-transformed cells, which included predominantly resident microglia from the brain and circulating blood monocytes (macrophages), comprising 30%–50% of the cellular content of these tumors (4). The glioma purity was closely related to patient prognosis (5, 6), implying that the glioma immune microenvironment was involved in key glioma biology, including prognosis, recurrence, and treatment response. Recently, many immune-related signatures were identified for glioma prognostic analysis and functional exploration. A ferroptosis-related gene signature was identified and correlated with the tumor immune microenvironment status in the study of Zheng et al. (7), and this signature displayed a predictive performance for glioma survival. Cheng et al. (8) performed a multi-omics integrated analysis and identified an immune-related gene signature (ABCC3, PDPN, and INA) to predict the prognosis, immune infiltration status, and chemotherapy response of LGG patients with epilepsy. Zhao et al. (9) performed a glioma immune subtype analysis based on 29 immune cell characterizations and defined three immune groups, named immune-H, immune-M, and immune-L. The redefined immune phenotypes were related to patient survival and contributed to the remodeling of the immunosuppressive microenvironment (9). However, in addition to immune cell infiltration, microenvironment features should also include tumor features, such as stromal remodeling, proliferation, and tumor procytokines, and consider the full range of immune-related characteristics. Therefore, it is necessary to characterize the glioma immune microenvironment based on sufficient samples from multiple cohorts, especially considering the immune cells surrounding the tumor, for further guiding the clinical prognosis.

In this study, by analyzing available glioma expression profiles with survival data of a total of 3,486 samples from eight cohorts, we utilized the Least Absolute Shrinkage and Selection Operator (LASSO) model to construct the Glioma MicroEnvironment Functional Signature (GMEFS) model, which consisted of 25 immune microenvironment signatures. To test the prognostic performance of GMEFS, we further obtained two independent glioma cohorts from The Cancer Genome Atlas (TCGA) database, and the nomogram was constructed for evaluating the prognostic performance. Meanwhile, the associations between GMEFS and glioma molecular subtypes, tumor purity, or stromal score, as well as immune cell infiltration, were explored. The GMEFS score was also evaluated in multiple-level brain tumor formation and glioma recurrence from a large number of glioma samples from multiple cohorts. Finally, we identified risk subpathways related to the GMEFS score and constructed a comprehensive drug–subpathway network for candidate target region screening, which provided important guidance for glioma clinical treatment.

MATERIALS AND METHODS
Publicly Available Training and Testing Cohort Datasets
We searched the available mRNA expression profiles with prognosis information from several tumor resources, such as the Gene Expression Omnibus (GEO) database, Chinese Glioma Genome Atlas (CGGA) database, and Pan-Cancer Analysis of Whole Genomes (PCAWG) database for glioma prognostic microenvironment identification. For the datasets from the GEO database, the cohorts with at least 40 samples were considered and a total of six public glioma cohorts were downloaded. We also collected two glioma cohorts (LGG and GBM) from TCGA database and the multi-omics data including gene expression, methylation level, and copy number variations (CNVs) from the Human Glioma Cell Culture (HGCC) collection as the independent testing set. Finally, 6,920 brain samples from 27 cohorts were included in our study, and the total information was shown in Table 1.

Immune Microenvironment Signatures
We collected 175 immune microenvironment-related signatures from diverse literature for glioma prognostic signature identification. In detail, 28 signatures were obtained from the work of Bindea et al. (10), 11 signatures were obtained from the work of Wolf et al. (11), 24 cell signatures were obtained from the work of Miao et al. (12), 22 immune signatures were obtained from CIBERSORT (13), 29 immune microenvironment signatures were obtained from the work of Bagaev et al. (14), 40 signatures were obtained from Cellmarker database (15), 4 microglia signatures were obtained from the work of Sala Frigerio et al. (16), 8 brain immune cell signatures were obtained from scREAD database (17), and 9 microglia subtype signatures were obtained from the work of Olah et al. (18) More detailed information is listed in Table S1.

The datasets from GEO, CGGA, and PCAWG databases were treated as the training set, and the datasets from TCGA were treated as the testing set. Based on the 175 tumor microenvironment signatures, we firstly utilized the single sample Gene Set Enrichment Analysis (ssGSEA) method implemented in the R package to calculate the normalized enrichment score (NES) for each glioma sample from the training set (19). To remove the potential batch effects from different cohorts, we further used Combat function to form a merged NES matrix for microenvironment signature identification. Finally, the prognostic performance of this signature was tested using testing datasets.

Construction of the Immune Microenvironment Risk Model
Based on the merged NES matrix, which consisted of 175 immune microenvironment signatures and 4,887 glioma samples, we firstly performed univariable Cox proportional hazards regression analysis using 3,486 samples with survival analysis. A set of 141 signatures was identified with a prognostic P-value <0.05. The detailed univariable Cox results, including the hazard ratio (HR) value, 95% CI, and P-values, of these microenvironment signatures were provided in Table S2.
The LASSO Cox regression model (20) was used to find the most useful prognostic markers among the 141 immune microenvironment signatures in the training cohort by the R package glmnet. Ultimately, 25 immune microenvironment features with non-zero coefficients were selected through LASSO Cox regression model analysis, and the optimal lambda value was determined by 10-fold cross-validation. The multivariable Cox proportional hazards regression analysis was further performed for these 25 immune microenvironment signatures obtained from the LASSO analysis, and the corresponding coefficients are presented in Table S3. Finally, a novel glioma prognostic signature, GMEFS, was constructed by comprehensively considering the coefficients of these 25 immune signatures. The formula was provided as follows:

$$GMEFS = \sum_{i=1}^{25} \log (HR_i) \times NES_i$$

where HR$_i$ is the HR and NES$_i$ is the NES for the ith immune microenvironment signature.

Functional Analysis and Differential Expression Analysis

The ESTIMATE score, tumor purity, and stromal and immune scores for each glioma sample were calculated by using ESTIMATE package in R with default parameters (21). The differential expression (DE) analyses for TCGA GBM and LGG cohorts were performed by the limma package in R (22).

Drugs–Subpathway Network

Functional enrichment analyses, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and subpathway analyses, were performed by using the clusterProfiler package in R (23), and the P-value was adjusted by the Benjamini and Hochberg method.

Drug–Subpathway Network

Based on the HGCC resource (24), we obtained the drug IC50 information, as well as gene expression, methylation, and CNV data for each GBM cell line. Firstly, based on the median IC50 value as cutoff, we defined two cell line groups, high IC50 groups and low IC50 groups. Then, based on these two groups, we respectively identified drug-related genes according to gene expression level, methylation condition, and CNV data. For gene expression profiles, the T-test was used. For methylation and CNV data, the Wilcoxon rank sum test was used. The cutoff for DE analysis was set as adjusted P-value <0.05. Finally, we evaluated the associations between DE genes and GMEFS subpathways by using the hypergeometric test method. The result with P-value <0.05 was considered as a significant association. An integrated drug–subpathway network was constructed by considering the significant drug–subpathway associations shared by two omics results.

Statistical Analysis

According to the GMEFS score, all glioma samples from both training and testing sets were classified into two groups based on...
the consistent cutoff as the training set. Then, the Kaplan–Meier (KM) curve and survival P-value calculated by the log-rank test were performed by using R survminer package. The glioma molecular subtypes (Classical-like, Codel, G-CIMP-high, G-CIMP-low, Mesenchymal-like, PA-like) of the glioma patients were obtained from a previous study (25). For both training and testing sets, a nomogram was formulated to provide a visualized risk prediction after each factor was assigned a score. A calibration plot was generated to assess the calibration ability of the nomogram (26). Nomograms and calibration plots were generated by using the rms package. The decision curve analysis (DCA) was performed by using dca package. All of the P-value results were considered statistically significant with P-values <0.05.

RESULTS

Identification of Glioma Immune Microenvironment Functional Signatures for Prognostic Analysis

Based on the training set that consisted of a total of 8 glioma cohorts, we constructed a microenvironment-based prognostic model named GMEFS (see Materials and Methods). The GMEFS consisted of 25 glioma immune microenvironment signatures, and the detailed LASSO results of these 25 signatures were displayed in Figures 1A, B. We calculated the GMEFS score for each glioma patient in the training cohort and stratified the patients into high or low GMEFS groups according to the median cutoff. As shown in Figure 1C, the samples with a high GMEFS score had a significantly shorter overall survival than samples with a low GMEFS score in the training cohort (P < 0.0001; log-rank test). The associations between each of the 25 immune microenvironment signatures and clinical survival are also shown in Figure 1D. To further examine the robustness of the GMEFS model, two independent glioma cohorts, GBM and LGG datasets, were also obtained as testing sets for the prognosis analysis (see Materials and Methods). With the same formula, the samples from the testing set were stratified into high and low GMEFS groups by the cutoff value obtained from the entire training set. As shown in Figures 1E, F, the samples with a high GMEFS score also had significantly worse overall survival than those who displayed a low GMEFS score in both GBM and LGG cohorts (GBM P = 0.0091, LGG P < 0.0001; log-rank test). Meanwhile, survival analysis for progression-free survival (PFS) was also performed, and the predictive performance of GMEFS in GBM (Supplementary Figure 1A, P = 0.015) and LGG (Supplementary Figure 1B, P < 0.0001) was confirmed. Similar results were observed in the entire TCGA cohort for both overall survival and PFS (Supplementary Figures 1C, D).

To further test the performance of predicting the glioma patient prognosis, a nomogram that integrated both the GMEFS and clinical factors (including gender and age) was constructed by using patients from the training set. Based on the nomogram results, a score can be calculated for a glioma patient for predicting the 3-, 5-, and 10-year overall survival for an individual, suggesting the power of GMEFS score in contributing the risk point (Figure 2A). The calibration curves for 3, 5, and 10 years of the training cohort were respectively illustrated in Figures 2B–D, showing the GMEFS’s performance in the glioma patient survival prediction.

The Clinical and Functional Characterizations Between the Samples With High and Low GMEFS Scores

To test the associations between GMEFS and molecular subtypes, we obtained the glioma subtype information (see Materials and Methods). As shown in Figure 3A, the samples from Classic-like, G-CIMP-low, and Mesenchymal-like subtypes displayed high GMEFS scores, whereas samples from the Codel subtype had a low GMEFS score, and the overall difference was significant. Moreover, an imbalance in terms of these five molecular subtypes within the two GMEFS group was observed (Figure 3B). Only small proportions of Codel subtype (6.5%) distributed in the high GMEFS group in contrast with 100% of Mesenchymal-like type and 100% of Classic-like type. Similar results were observed between molecular subtype and GBM GMEFS groups. Then, the correlations between tumor purity, stromal characterization, and GMEFS score were also explored. It was observed that the GMEFS score was positively correlated with the stromal score, immune score, and ESTIMATE score, whereas it was negatively correlated with tumor purity for TCGA LGG cohorts (Figure 3C), showing that the GMEFS score was a presentation of the immune microenvironment characterization.

Some potential factors that determine brain tumor immunogenicity, including macrophage regulation, homologous recombination deficient (HRD), TGF-beta response, and wound healing, were compared between the high GMEFS group and the low GMEFS group from TCGA LGG cohort (Figure 3D). The mean activity values for other factors of the high GMEFS group were significantly higher than those of the low GMEFS group. In addition, the samples with a higher GMEFS displayed a higher proliferation score than that of patients with a lower GMEFS, which was consistent with the prognostic performance of GMEFS. Overall, the differences in brain tumor immunogenicity between the GMEFS groups were significant, and the high GMEFS group had a relatively high immunogenicity. Next, we identified 83 upregulated genes in the high GMEFS group vs. the low GMEFS group by the cutoffs of log-fold change (FC) >1.5 and false discovery rate (FDR) <0.05. The GO biological process terms enriched by these genes included many immune-related processes, such as neutrophil activation, antigen processing and presentation, and neutrophil-mediated immunity (Figure 3E). Similar GO biological process terms and KEGG pathway results were illustrated in TCGA-GBM cohort (Supplementary Figure 2).

Furthermore, we quantified these 83 LGG gene signatures in data from the Ivy Glioblastoma Atlas Project (IGAP), which performed RNA sequencing (RNA-seq) on microdissections of glioma anatomical structures from hematoxylin and eosin (H&E) staining (Ivy Glioblastoma Atlas Project; http://glioblastoma.alleninstitute.org). The higher expression activity of these genes was enriched in samples from the hyperplastic
These gene signatures displayed a lower expression level in infiltrating tumor and leading edge (Figure 3F). To test the glioma association of 83 genes, we further obtained several glioma-related gene sets from a previous study (27). As shown in Supplementary Figure 3A, these genes displayed a significant overlap with GBM disease genes. These GBM genes were also enriched in the samples with a high GMEFS score compared to those with a low GMEFS score (Supplementary Figure 3B).

**Immune Cell Proportion Analyses for Samples With High and Low GMEFS Scores**

To further explore the different immune cell proportions within the two GMEFS groups, we performed CIBERSORT analysis with 1,000 permutations for glioma cohorts (13). As shown in Figures 4A, B, the proportions of 22 common immune cell types of the two GMEFS groups of LGG were displayed. The samples from the low GMEFS group had significantly higher proportions of plasma cells, monocytes, activated mast cells, and eosinophils than those of samples from the high GMEFS group (P < 0.05). Correspondingly, the proportions of memory resting CD4 T cells, M2 macrophages, and CD8 T cells in the high GMEFS group were significantly higher than those in the low GMEFS group (P < 0.05). We further studied the correlation between the GMEFS score and the proportion of immune cell infiltration. The results revealed that CD8 T cells and M2 macrophages were positively correlated with the GMEFS, and activated mast cells and T helper cells were negatively correlated with GMEFS (Figure 4C). By comparing brain cell-type marker gene from the PanglaoDB database (28), we identified 9 cell types associated with the two GMEFS groups, including microglia, astrocytes, and oligodendrocyte progenitor cells (Figure 4D). Parenchymal microglia are the major component of myeloid cells involved in heterogeneous Central Neural System (CNS).
immune microenvironment (29, 30), and microglia play important roles in the brain-related tumors, including glioma (31).

**The Involvement of GMEFS in Glioma Formation and Recurrence**

To test the performance of the GMEFS in glioma formation and recurrence, we further obtained the glioma datasets from the GEO database (Table 1). The GMEFS scores were calculated for each analytical sample, and the difference was evaluated between glioma and normal samples, as well as recurrence glioma and primary glioma samples. As shown in Figure 5A, among 14 independent glioma cohorts, the glioma samples displayed consistently higher GMEFS scores than those in normal samples in a total of 12 cohorts. These significant cohorts contained glioma samples (11/12) and Diffuse Intrinsic Pontine Glioma (DIPG) samples (1/12). In addition, within 2 of 7 glioma cohorts, the recurrence samples also displayed higher GMEFS scores than those in primary samples (Figure 5B). All these findings show that the GMEFS was not only a risk characterization for evaluating high-risk samples from low-risk samples but also could distinguish glioma samples from normal samples, considering the diagnosis index for glioma patients. As shown in Figures 5C, D, within two glioma cohorts with available stage information, we observed that the samples with a higher stage displayed a higher GMEFS score than samples with a lower stage, which was consistent with the prognostic performance of the GMEFS groups (GSE16011, P = 1.9e-08; GSE4290, P < 2.2e-16). Using these testing sets from the GEO, we further confirmed the GMEFS difference in histology subtypes and molecular subtypes, which was also consistent with previous results (GSE60898 and GSE72951 from Figures 5E, F, Figure 3A). As shown in GSE116520 (Figure 5G), the GMEFS score was also related to glioma region distribution; GMEFS was higher in core tumor tissue and lower in non-neoplastic brain tissue.

**Subpathway-Level Exploration Driven by GMEFS and Drug–Subpathway Network**

In our previous studies (32, 33), we observed that the regions of the whole pathway, which is also named as subpathway, was closely related to disease formation and progression. The related results further confirmed that the subpathway displayed more advantages over the whole pathway with providing detailed biological information. We firstly obtained the subpathway list from subpathwayMiner R package with the default parameters (33). Based on the training, TCGA-GBM, and TCGA-LGG cohorts, we utilized the GSEA algorithm to identify the significantly enriched subpathways between the high GMEFS and low GMEFS groups. As shown in Figures 6A, B, a total of 32 risk subpathways were shared by three glioma cohorts. These risk subpathways were derived from Focal adhesion, ECM–receptor interaction, and pathways in cancer. Notably, a total of 8 subpathways derived from Focal adhesion were identified.
Take one subpathway (path:04510_9) as an example, and the subpathway activity was calculated for the corresponding tumor samples. As shown in Figures 6C–E, the Focal adhesion subpathway could distinguish all samples into two groups with significant prognosis (Training cohort, \( p < 0.0001 \); TCGA-GBM, \( p = 0.017 \); TCGA-LGG, \( p < 0.0001 \)). To explore the detailed associations between antineoplastic compounds and GMEFS subpathways shared by two cohorts, we constructed a multi-omic integrated network based on HGCC resource (see Materials and Methods). As shown in Figure 6F, many subpathways were targeted by many candidate drugs, such as path: 04062_2 from chemokine signaling pathway and path: 04510_9 from focal adhesion. The subpathway 04062_2 was targeted by many approved molecules, such as mesalamine, pamelar, angormin, and amlodipine. Some subpathways from the same whole pathway (path: 04510) were commonly targeted by some molecules, such as etoposide, paludrine, and suloctidil. Notably, as an experimental drug, suloctidil was closely related to many risk subpathways. Furthermore, we obtained several drug target genes for glioma collected from a recent study (34). We observed that many subpathways within networks contained known drug targets. Notably, three subpathways (path: 04510_8, _10, and _12) from Focal adhesion contained four target genes, including PDGFRA, EGFR, and SRC. The systematically reconstructed drug–subpathway network provided a novel framework for identifying subpathway regions as candidate therapy targets and screening-approved or experimental molecules as novel drugs for clinical use.

FIGURE 3 | Clinical significance and functional analysis of the two GMEFS groups in TCGA-LGG. (A) Violin plot illustrating the distribution of the GMEFS score in different intrinsic molecular subtypes. (B) Sankey plot of the GMEFS values in subtypes with different intrinsic molecular subtypes. (C) Correlations between the GMEFS score, stromal score, immune score, ESTIMATE score, and tumor purity. (D) Comparison of Macrophage Regulation, Proliferation, TGF-beta Response, Homologous R Defects, Wound Heal between the high and low GMEFS groups. TCGA-LGG patients were classified into low and high GMEFS groups. Visualization of the top 10 enriched biological processes (E) by the upregulated differentially expressed genes (DEGs) in the high vs. low GMEFS groups. (F) Heatmap of the upregulated DEGs in the Ivy Glioblastoma Atlas Project (IGAP) dataset. Samples were ordered along the row by the structure regions.
DISCUSSION

In this study, the relative quantitative infiltrate levels of 175 immune microenvironment signatures in a total of 4,887 glioma patients from multiple cohorts were estimated, and a novel prognostic model (GMEFS) consisting of functional signatures was constructed. To test the predictive performance of the GMEFS, we further obtained independent glioma cohorts from TCGA. In addition, many other glioma cohorts from the GEO database were also obtained to analyze the different GMEFS scores between brain tumor and normal samples. Data from one glioma cell line from HGCC were utilized to construct a drug-related network. In a word, a total of 6,920 brain samples were utilized in this study to comprehensively identify and explore the glioma immune microenvironment characterization for prognosis analysis.

For the input in LASSO-Cox regression analysis, we have collected as many tumor-related microenvironment signatures as possible, including the functional signatures from the study of Bagaev et al. (14). A total of 175 immune microenvironment signatures were collected from diverse resources in this study. The 25 functional signatures in the GMEFS included 17 risk signatures with HR > 1 and 8 protective signatures with HR < 1. Among these 25 immune microenvironment signatures, some signatures were specific for the brain tissue, such as oligodendrocytes and pericytes from the study of Jiang et al. (17) and microglia clusters from the study of Olah et al. (18). Also, some neuron-related signatures were included in the GMEFS, such as Immature olfactory sensory neuron and late activated neural stem cell (as risk factors) and Olfactory sensory neuron (as protective factor). Moreover, some tumor characterizations were also included, such as protumor cytokines, matrix, and matrix remodeling from the study of Bagaev et al. (14), and all of these signatures displayed risk distribution in the GMEFS model. From another tumor study of Wolf et al. (11), two module signatures that the authors defined, Development/differentiation module and Stromal mixed module, were also identified.

Recently, a large scale of bioinformatics studies utilized public data resources to identify glioma prognostic signatures, including gene signatures (35–40), lncRNA signature (41), and gene-set signature (42, 43). The summary of all of these prognostic studies
and our study was displayed in Table S4. Most of the previous studies utilized less than 6 cohorts to identify and validate the prognostic model, and the most frequent training sets were from TCGA or CGGA. Lin et al. (35) constructed a 5 gene-based prognostic model that was derived from hypoxia function to predict the glioma survival. The glioma cohorts from CGGA were utilized for model construction (35). Tan et al. (38) constructed a 6-gene risk model based on glioma samples from TCGA and validated it using CGGA samples. Some other studies performed the survival analysis based on some key genes or gene sets without identifying signature procedures (39, 42). Regarding both the construction and validation of the prognostic model, an adequate number of the training set and testing set were necessary for a robust risk model analysis. In our GMEFS construction, we utilized a total of 3,486 samples with survival information from 8 glioma cohorts to perform signature identification, and a total of 27 multiple cohorts were included in our analysis.

Based on TCGA-LGG cohort with available treatment information, we further observed that the GMEFS was significantly decreased in patients with complete or partial response when compared with those with stable or progressive disease. The effectiveness of the GMEFS value in predicting the response of cancer patients to immunotherapy was also verified (Supplementary Figure 4). TCGA-GBM, which contained a limited number of samples with available response information, was not included in this analysis.

Some limitations were also displayed in this study. Firstly, the signatures involved in the GMEFS were an independent functional set, and the complex interactions between tumor cells and immune cells were not explored. Secondly, the key gene or protein molecules underlying the GMEFS should further be identified, or the key signatures of the GMEFS should be further mined. However, it also displayed advantages over other studies that a total of more than 6,000 brain samples were utilized for constructing and verifying the prognostic and
distinguishing glioma sample performance. Meanwhile, we developed a novel framework to identify functional signatures and explore drug–subpathway associations for glioma treatment guidance.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**AUTHOR CONTRIBUTIONS**

CZ, WM, and YXZ analyzed and interpreted the data. CZ, GT, YX, and FL performed the bioinformatics analyses. YZ, XZ, ZZ, GT, and YPZ performed the biological evaluation. CZ, YX, and YPZ wrote the article. All authors read and approved the final article.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grant Nos. 62172131 and 62101164).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.853074/full#supplementary-material
Supplementary Figure 1 | Kaplan-Meier estimate of the overall survival of the TCGA-GBM (PFS) (A), TCGA-LGG (PFS) (B), TCGA-GBM/LGG (OS) (C) and TCGA-GBM/LGG (PFS) (D) divided by two GMEFS model.

Supplementary Figure 2 | TCGA GBM patients were classified into high and low GMEFS groups. Visualization of the top 10 enriched biological processes (A) and the top 10 enriched KEGG pathways (B) by the DEGs in the high versus low GMEFS groups.

Supplementary Figure 3 | (A) the venn plot between DEGs from TCGA LGG high GMEFS and low GMEFS groups, and glioma related gene set.

REFERENCES

1. Louis D. Molecular Pathology of Malignant Gliomas. *Ann Rev Pathol* (2006) 1:97–117. doi: 10.1146/annurev.pathol.1.110304.100043
2. Gladson C, Prayson R, Liu W. The Pathobiology of Glioma Tumors. *Ann Rev Pathol* (2010) 5:33-50. doi: 10.1146/annurev-pathol-121808-102109
3. Mishel P, Cloughesy T. Targeted Molecular Therapy of GBM. *Brain Pathol* (Zurich Switzerland) (2003) 13:52–61. doi: 10.1111/j.1750-3639.2003.tb00006.x
4. Simons G, Pong W, Emnett R, White C, Gianino S, Rodriguez F, et al. Neurofibromatosis-1 Heterozygosity Increases Microglia in a Spatially and Temporally Restricted Pattern Relevant to Mouse Optic Glioma Formation and Growth. *J Neuropathol Exp Neurol* (2011) 70:51-62. doi: 10.1097/NEN.0b013e3182032d47
5. Aran D, Sirota M, Butte A. Systematic Pan-Cancer Analysis of Tumour Landscape in Human Cancer. *Nat Commun* (2013) 4:2612. doi: 10.1038/ncomms3612
6. Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, et al. Tumor Purity as an Underlying Key Factor in Glioma. *Clin Cancer Res* (2017) 23:6279–91. doi: 10.1158/1078-0432.CCR-16-2598
7. Zheng Y, Ji Q, Xie L, Wang C, Yu C, Wang Y, et al. Ferroptosis-Related Gene Modulate the Microglia Response to A (4):1293 ’101769 for Alzheimer Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques. *Cell Rep* (2019) 27 (4):1293–306.e5. doi: 10.1016/j.celrep.2019.03.099
8. Jiang J, Wang C, Qi R, Fu H, Ma Q, sCRAD: A Single-Cell RNA-Seq Database for Alzheimer’s Disease. *Scienced* (2020) 23:101769. doi: 10.1016/j.jsci.2020.101769

(B) The GSEA plot for GBM disease genes in the all rank genes by two GMEFS groups.

Supplementary Figure 4 | The associations between GMEFS groups and therapy response in the TCGA LGG cohorts. (A) Boxplot illustrating the distribution of GMEFS for patients with different therapy responses. Significance was determined by the Wilcoxon test. (B) Bar graph illustrating the numbers of clinical responses to therapy in the high and low GMEFS groups. (C) Waterfall plot illustrating the distribution of GMEFS for patients with different therapy responses.

18. Olah M, Menon V, Habib N, Taqa M, Ma Y, Yung C, et al. Single Cell RNA Sequencing of Human Microglia Uncovers a Subset Associated With Alzheimer’s Disease. *Nat Commun* (2020) 11:0129. doi: 10.1038/s41467-020-19737-2
19. Hanzelmann S, Castelo R, Guinney J. Gsva: Gene Set Variation Analysis for Microarray and RNA-Seq Data. *BMC Bioinf* (2013) 14:7. doi: 10.1186/1471-2105-14-7
20. Goeman J, Li Penalized Estimation in the Cox Proportional Hazards Model. *Biom J Biom Z* (2010) 52(1):70–84. doi: 10.1002/bimj.200900028
21. Yoshihara K, Shahmoradgoli M, Martinez E, Vegenas R, Kim H, Torres-Garcia W, et al. Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data. *Nat Commun* (2013) 4:2612. doi: 10.1038/ncomms3612
22. Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W, et al. Limma Powers Differential Expression Analyses for RNA-sequencing and Microarray Studies. *Nucleic Acids Res* (2015) 43:e47. doi: 10.1093/nar/gkv007
23. Yu G, Wang L, Han Y, He Q, Clusterprofiler: An R Package for Comparing Biological Themes Among Gene Clusters. *Omics* (2012) 16:284–7. doi: 10.1089/omi.2011.0118
24. Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, et al. A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. *Cell Rep* (2020) 32:107897. doi: 10.1016/j.celrep.2020.107897
25. Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Ou T, et al. The Immune Landscape of Cancer. *Immunity* (2018) 48:812–30.e814. doi: 10.1016/j.immuni.2018.03.023
26. Isakson A, Schrag D, Raj G, Panagaces K. How to Build and Interpret a Nomogram for Cancer Prognosis. *J Clin Oncol* (2008) 26:1364–70. doi: 10.1200/JCO.2007.12.9791
27. Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy D, et al. A Genome-Wide Positioning Systems Network Algorithm for in Silico Drug Repurposing. *Nat Commun* (2019) 10:3476. doi: 10.1038/s41467-019-10744-6
28. Fränzén O, Gan L-M, Björkergen JLM. PangloaoDB: A Web Server for Exploration of Mouse and Human Single-Cell RNA Sequencing Data. *Database* (Oxford) (2019) 2019:baz046. doi: 10.1093/database/baz046
29. Prinz M, Priller J, Susodhi S, Ransohoff R. Heterogeneity of CNS Myeloid Cells and Their Roles in Neurodegeneration. *Nat Neurosci* (2011) 14:1227–35. doi: 10.1038/nn.2923
30. Prinz M, Priller J. Microglia and Brain Macrophages in the Molar Age: From Origin to Neuropsychiatric Disease. *Nat Rev Neurosci* (2014) 15:3090–12. doi: 10.1038/nrn3722
31. Müller S, Kohanbash G, Liu S, Alvarado B, Carrera D, Bhaduri A, et al. Single-Cell Profiling of Human Gliomas Reveals Macrophage Ontogeny as a Basis for Regional Differences in Macrophage Activation in the Tumor Microenvironment. *Genome Biol* (2017) 18:234. doi: 10.1186/s13059-017-1362-4
32. Li C, Han J, Yao Q, Zou C, Xu Y, Zhang C, et al. Subpathway-GM: Identification of Metabolic Subpathways via Joint Power of Interesting Genes and Metabolites and Their Topologies Within Pathways. *Nucleic Acids Res* (2013) 41:e101. doi: 10.1093/nar/gkt161
33. Li C, Li X, Miao Y, Wang Q, Jiang W, Xu C, et al. SubpathwayMiner: A Software Package for Flexible Identification of Pathways. *Nucleic Acids Res* (2009) 37:e131. doi: 10.1093/nar/gkp667
34. Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, et al. Therapeutic Target Database Update 2022: Facilitating Drug Discovery With Enriched Comparative Data of Targeted Agents. *Nucleic Acids Res* (2022) 50:D1398–407. doi: 10.1093/nkab953
35. Lin W, Wu S, Chen X, Ye Y, Weng Y, Pan Y, et al. Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups. *Front Oncol* (2020) 10:796. doi: 10.3389/fonc.2020.00796

36. Wu F, Li G, Liu H, Zhao Z, Cai R, Liu Y, et al. Molecular Subtyping Reveals Immune Alterations in IDH Wild-Type Lower-Grade Diffuse Glioma. *J Pathol* (2020) 251:272–83. doi: 10.1002/path.5468

37. Lin S, Xu H, Zhang A, Ni Y, Xu Y, Meng T, et al. Prognosis Analysis and Validation of M6a Signature and Tumor Immune Microenvironment in Glioma. *Front Oncol* (2020) 10:541401. doi: 10.3389/fonc.2020.541401

38. Tan Y, Li Y, Yan T, Xu Y, Liu B, Yang J, et al. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma. *Front Immunol* (2021) 11:698278. doi: 10.3389/fimmu.2021.698278

39. Lu J, Peng Y, Huang R, Feng Z, Fan Y, Wang H, et al. Elevated TYROBP Expression Predicts Poor Prognosis and High Tumor Immune Infiltration in Patients With Low-Grade Glioma. *BMC Cancer* (2021) 21:723. doi: 10.1186/s12885-021-08456-6

40. Li H, Wang G, Wang W, Pan J, Zhou H, Han X, et al. A Focal Adhesion-Related Gene Signature Predicts Prognosis in Glioma and Correlates With Radiation Response and Immune Microenvironment. *Front Oncol* (2021) 11:698278. doi: 10.3389/fonc.2021.698278

41. Yu W, Ma Y, Hou W, Wang F, Cheng W, Qiu F, et al. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma. *Front Immunol* (2021) 12:706936. doi: 10.3389/fimmu.2021.706936

42. Zhao W, Ou G, Lin W. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. *Front Immunol* (2021) 12:682415. doi: 10.3389/fimmu.2021.682415

43. Zolotovskaia M, Tkachev V, Sorokin M, Garazha A, Kim E, Kantelhardt S, et al. FREM2 Algorithmically Deduced Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. *Cancers* (2021) 13(16):4117. doi: 10.3390/cancers13164117

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Zhang, Tan, Mi, Zhong, Zhang, Zhao, Li, Xu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.